Moderna Halts Plan for Japan mRNA API Facility Amid Market Shifts, Completes Enzymatics R&D Site at Shonan iPark

Moderna provided an update on its two planned research and manufacturing facilities at Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefectu...

July 22, 2025 | Tuesday | News
AGC Introduces New Surfactant- and Fluorinated Solvent-Free Grades in AFLAS™ FFKM Series

AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materia...

July 18, 2025 | Friday | News
Japan’s Chugai and Singapore’s Gero Join Forces to Advance Antibody Therapies Targeting Aging via AI and Human Data

Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through...

July 08, 2025 | Tuesday | News
Orchard Therapeutics Completes Global Enrollment in Pivotal MPS-IH Gene Therapy Trial Ahead of Schedule

Orchard Therapeutics, a Kyowa Kirin company, announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of ...

July 08, 2025 | Tuesday | News
Nxera Pharma to Receive US$4.8 Million in Milestone Payments as Centessa Advances Orexin Agonist into Clinical Development

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone paym...

July 07, 2025 | Monday | News
Abinopharm Reports Positive Clinical Trial Outcomes for Oral Dr.Ergo® L-Ergothioneine in Enhancing Skin Health

Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EG...

July 07, 2025 | Monday | News
Asahi Kasei Pharma Begins Phase III Trial in Japan of ART-123 for Preventing Chemotherapy-Induced Peripheral Neuropathy

Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...

July 03, 2025 | Thursday | News
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial of JR-141 for Hunter Syndrome Across the U.S., Latin America, and Europe

-JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III cli...

July 03, 2025 | Thursday | News
Valneva Partners with CSL Seqirus to Distribute Chikungunya, Japanese Encephalitis, and Cholera Vaccines in Germany

Valneva SE, , a specialty vaccine company, announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companie...

June 30, 2025 | Monday | News
AGC Biologics Expands Global Cell Therapy Network with New Services Launch in Yokohama, Japan

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc....

June 26, 2025 | Thursday | News
Nutriband and Kindeva Complete Commercial Manufacturing Scale-Up for AVERSA™ Fentanyl, Advancing World’s First Abuse-Deterrent Opioid Patch

Nutriband Inc.  a company engaged in the development of prescription transdermal pharmaceutical products, announced that it has completed commercial...

June 24, 2025 | Tuesday | News
Sanofi Begins Early Q3 Shipments of Beyfortus to Meet Growing Demand for RSV Protection in Infants

Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV)...

June 10, 2025 | Tuesday | News
SOLVE FSHD and Modalis Partner to Advance CRISPR-Based Epigenome Editing Therapy for Muscular Dystrophy

-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...

June 09, 2025 | Monday | News
Samsung Bioepis Partners with NIPRO to Advance Biosimilars in Japan

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...

June 09, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close